Repare Therapeutics: Positive Results of Lunresertib and Camonsertib

Repare Therapeutics Inc. recently shared some exciting news from their MYTHIC Phase 1 gynecologic expansion clinical trial. The study looked at the combination of lunresertib and camonsertib (Lunre+Camo) in patients with endometrial cancer and platinum-resistant ovarian cancer. The results showed that heavily-pretreated patients on this combination achieved a 25.9% overall response rate (ORR) in endometrial cancer and a 37.5% ORR in platinum-resistant ovarian cancer.

What’s especially promising is that nearly half of the patients with gynecologic cancers maintained progression-free survival at 24 weeks, which is a significant improvement compared to the current standard of care. This suggests that Lunre+Camo could be a potential game-changer for these patients.

Lunresertib is a first-in-class precision oncology small molecule PKMYT1 inhibitor, while camonsertib is a best-in-class oral small molecule inhibitor of ATR, an essential component of the DNA damage response pathway. The combination of these two drugs showed positive responses in patients with challenging gynecologic cancers.

The Company plans to kick off a registrational Phase 3 trial of Lunre+Camo in endometrial cancer in the second half of 2025. This trial will further explore the effectiveness of this combination as a potential new treatment option for patients with endometrial cancer.

Repare’s President and Chief Executive Officer, Lloyd M. Segal, said, “These patients need new treatment options, and our results support the potential for Lunre+Camo to make a real, positive difference if approved, particularly as a chemotherapy alternative.” The Company has received positive feedback from regulatory agencies in the US and Europe, indicating a promising future for Lunre+Camo.

Leading experts in the field, like Brian Slomovitz, MD, MS, FACOG, Director of Gynecologic Oncology at Mount Sinai Medical Center, are excited about the potential of Lunre+Camo as a new treatment option for patients with endometrial and platinum-resistant ovarian cancers. This innovative approach offers hope for those with limited treatment options and resistant tumors.

Repare is in close communication with regulatory agencies like the FDA and the European Medicines Agency to advance the development of Lunre+Camo in gynecologic tumors. Plans for Phase 3 trials and additional studies are in the works to accelerate the availability of this promising treatment option.

This is an important step forward in the fight against gynecologic cancers, and the results of the MYTHIC trial are a source of hope for patients and medical professionals alike. Repare will be hosting a conference call and webcast to discuss these results further, underscoring their commitment to transparency and sharing important updates with the community.